American Society of Clinical Oncology

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.

New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.

The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

Patients with the rare cancer condition requires both a collaborative physician network and proven therapies.

New phase 3 trial results show the monoclonal antibody plus pomalidomide and dexamethasone improves progression free survival and overall response rate among patients with RRMM.

Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.

Phase 3 results show the therapy plus recombinant human hyaluronidase is comparably safe and effective for patients with relapsed-refractory multiple myeloma.

A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.

New analysis shows patients from either of these populations often take longer to be diagnosed with leukemia or lymphoma than their male or median-income counterparts.

A new study shows a profound lack of genetic markers, allowing doctors to standardize treatment.

A new study shows that adding this pair of drugs reduces costs and side effects while increasing efficacy.

Investigators from St. Jude's Children Research Hospital presented the results of the phase 1 trial at ASCO 2019 in Chicago.

Investigators conducted an open-label, randomized, multi-center phase 2 study of VIT and vincristine with irinotecan without temozolomide that included 120 patients from 37 European centers.

A study presented at ASCO 2019 examined the differences between hospitalization cost and length of stay among pancreatic cancer patients based on location of the disease.

Pauline Funchain MD, shares how artificial intelligence may serve as a potential breakthrough for treating rare diseases in the future.

E. Anders Kolb, MD, discusses the exciting possibilities of using genomic technologies to stratify pediatric cancer patients.

Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.

Manmeet Ahluwalia, MD, discusses the challenges patients and providers face when it comes to rare cancers.

E. Anders Kolb, MD, outlines the challenges in diagnosing pediatric cancers and explains how molecular events define disease outcomes.

E. Anders Kolb, MD, emphasizes the difference between pediatric and adult cancers and the need to develop new treatments developed specifically for children.

Pauline Funchain, MD, discusses the use of multiplex germline testing for rare diseases and cancers and explains the benefits of uncovering genetic factors.

Owen A. O’Connor, MD, PhD, outlines the importance of clinical trials and reviewed strides made in lymphoma treatments.

Dr Meletios A. Dimopoulos, discusses the use of ibrutinib combined with rituximab for the treatment of patients with Waldenström macroglobulinemia.

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois, June 1-5, 2018, featured data from numerous studies and advancements being made in rare cancers. Here are 5 key takeaways from the meeting.

Phase 1/2a clinical trial (NCT02253212) data on ultrasound-induced blood-brain barrier (BBB) opening for brain disorders like recurrent glioblastoma.

Iobenguane I 131 (AZEDRA) has been shown to be effective in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para).

The use of the maintenance regimen increased both 5-year disease-free survival (DFS) and 5-year overall survival (OS) in rhabdomyosarcoma.

Pauline Funchain MD, explains her research which focuses on assessing possible underlying genetic and familial factors in melanomas.